Evidence mapPaperPMID 41800437Full record

ReviewInternational journal of nanomedicine2026

Innovative Strategies of Nanocapsules for Maximizing Efficacy in Tumor Immunotherapy.

Yizhao Jia, Chunhua Wang, Wangrui Liu, Zhijie Xu, Wei Zhu, Zhifeng Liu

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yizhao JiaDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Chunhua WangDepartment of Oral Bioscience, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Wangrui LiuDepartment of Thoracic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People's Republic of China.
Zhijie XuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.ORCID 0000-0003-2047-883X
Wei ZhuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Zhifeng LiuDepartment of Urology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review explores nanocapsules as a versatile platform to overcome the limitations of drug resistance inherent in conventional cancer therapy and immunotherapy. These nanosystems are capable of enhancing drug delivery, facilitating immune activation and modulating the tumor microenvironment. The review systematically classifies nanocapsules into distinct categories, including bacterial carriers, protein frameworks, lipids, metals, inorganic non-metals and polymers. Key findings demonstrate that nanocapsules possess the capacities for targeted delivery, stimuli-responsive release and synergistic combination with chemotherapy, radiotherapy, as well as photodynamic/photothermal therapy. However, several hurdles remain for their clinical translation, namely insufficient clinical trials and challenges in production scalability. In addition, the review discusses the impacts of different physical properties of nanocapsules and the underlying mechanisms of drug resistance. By uniquely integrating the classification of nanocapsules with corresponding therapeutic strategies, this review provides valuable insights for improving the efficacy of tumor immunotherapy.

Indexed as

ImmunotherapyNanocapsulesNeoplasmsAnimalsAntineoplastic AgentsCombined Modality TherapyDrug Delivery SystemsHumansTumor MicroenvironmentAntineoplastic AgentsNanocapsulescancer immunotherapycombined therapydrug deliverynanocapsulestumor microenvironment

Identifiers

PMID41800437
PMCPMC12967092

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.